Clinical Trial Update: A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma [Phase 3]

View source ↗

Summary

Final results from a Phase 3 trial comparing NKTR-214 (bempegaldesleukin) plus nivolumab versus nivolumab alone in previously untreated inoperable or metastatic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• NKTR-214 (bempegaldesleukin)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2022-12-19